Sarepta Therapeutics enters the final day of September with short sellers rebuilding positions, options turning modestly more defensive, and the stock off 10% on the week to $18.64, all against a backdrop of sharply divided Street opinion on Elevidys.
The short positioning story is the clearest signal this week. Short interest has climbed to 23.4% of the free float, up nearly 5% week-on-week, and is now running at roughly 24.6 million shares. That follows a broader drawdown from a peak above 27 million shares in mid-August, so the direction of travel has reversed. The FINRA fortnightly figure, settled as of September 15, put official short shares at 25.4 million with a days-to-cover of 8, a meaningful friction figure for anyone trying to close in a hurry. Borrowing costs tell a different story: the cost to borrow is just 0.43%, near a 30-day low, and availability is ample at 530% of current short interest, meaning there are roughly five shares available to lend for every one already borrowed. Bears are adding, but the borrow market is not punishing them for it.
Options are showing a mild shift in the same direction. The put/call ratio has moved to 0.56, above its 20-day average of 0.53 by about 1.4 standard deviations. That is not a panic reading, the 52-week high is 0.97, but the drift higher over the past two sessions is consistent with some incremental hedging as the stock breaks below $20. The ORTEX short score has also ticked up this week, reaching 64.9 on September 29 from 62.3 a week earlier, a steady grind rather than a spike, but the direction has been consistent for five consecutive sessions.
The Street is about as divided as the data. Bulls point to Sarepta's position as a commercial-stage rare disease company with four approved DMD therapies generating real revenue, and the unmet need in neuromuscular disorders remains large. Wolfe Research upgraded to Outperform in early July with a $27 target, and Oppenheimer and Mizuho each carry Outperform ratings with targets of $37 and $31 respectively. The bear case is harder to dismiss, however. Postmarketing analysis of 715 commercially treated Elevidys patients showed a 19% overall treatment-related acute liver injury rate, with serious ALI running at 7% to 9% and a 24% incidence in patients aged 12 and over. EMBARK missed its primary endpoint, and regulators have questioned the statistical basis for non-ambulatory claims. Citigroup and HC Wainwright both carry Sell ratings, and Needham reiterated its Underperform view as recently as September 28. Piper Sandler cut its target from $23 to $20 in July while staying Neutral. The consensus price target of $21.73 sits about 17% above the current price, but the dispersion is wide enough that the mean is not particularly informative.
On valuation, the stock trades at roughly 6x trailing earnings and 1.15x book, with EV/EBITDA near 11x. Each of those multiples has contracted over the past 30 days, the price-to-book ratio is down about 0.16 turns over the month and PE has compressed by roughly half a turn. Factor scores are generally soft: EPS surprise ranks in the 8th percentile and EPS momentum over both 30 and 90 days ranks in the low 20s, signalling that estimate revisions have been running against the stock. The forward earnings yield factor is a marginal positive at the 69th percentile.
The alt data layer offers one piece of colour worth noting. Medicaid reimbursements for Sarepta's drugs came in at $97.8 million in the quarter to January 2026, down 20% on the same quarter a year earlier, with Medicaid prescription volumes down 30% year-on-year over the same period. These are CMS figures, not ORTEX estimates, and neither dataset has been measured to lead Sarepta's reported financials, so they are context rather than signal. Still, a 30% drop in Medicaid script volume is not a benign backdrop for the revenue line. Wikipedia traffic has also been running about 1.8 standard deviations above its own 90-day average as of September 23, suggesting retail attention has picked up, likely reflecting the safety news flow.
The next earnings print is scheduled for November 4. Between now and then, the key variable is whether Elevidys safety disclosures attract further regulatory comment and whether commercial uptake data from Q3 can offset the Medicaid headwind visible in the government reimbursement figures.
See the live data behind this article on ORTEX.
Open SRPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
